Integrated DNA Technologies (IDT) showcased a new CRISPR off-target site nomination method designed to streamline discovery-to-confirmation by boosting high-confidence targets and reducing sequence noise. In a benchmarking study in Nature Communications, IDT reported UNCOVERseq’s analytical sensitivity of nearly 98% and said the workflow can run in cell lines under promiscuous editing conditions. The approach builds on the GUIDE-seq framework licensed by IDT, but modifies tagging to reduce clutter from non-informative byproducts. The company positions the tool as part of an end-to-end gene editing services effort, including standardized safety assessment. For gene-editing developers, improved off-target triage can accelerate timelines to confirmatory experiments and support stronger preclinical safety packages.